- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Panel studies medication problems of elderly
PHILADELPHIA - The American Society of Consultant Pharmacists will form an independent, interdisciplinary panel with the Alliance for Aging Research to examine medication-related problems in nursing facilities, the association announced at its annual meeting in November.
PHILADELPHIA - The American Society of Consultant Pharmacists will form an independent, interdisciplinary panel with the Alliance for Aging Research to examine medication-related problems in nursing facilities, the association announced at its annual meeting in November.
The panel will prepare a report recommending public policy actions for Congress. The ASCP hopes that policy-makers will strengthen the role of consultant pharmacists as medication experts for the elderly, according to R. Tim Webster, executive director of the ASCP.
According to a study supported by the ASCP's Research and Education Foundation, published in the Oct. 13 issue of Archives of Internal Medicine, the United States saves $3.6 billion annually on medication-related problems, and improves patient outcomes by 43% through pharmacist-conducted drug-regimen reviews in nursing facilities. The study estimated that preventable medication-related problems in nursing homes could cost as much as $7.6 million per year without the intervention of consultant pharmacists. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
FDA Approves AstraZeneca’s Calquence for Previously Untreated Mantle Cell Lymphoma
January 17th 2025Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously untreated mantle cell lymphoma.
